With box warnings

Without box warnings

Branded

Generic

3 results

erbitux
(cetuximab)
ImClone LLC
Usage: ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.
portrazza
(necitumumab)
Eli Lilly and Company
Usage: PORTRAZZA™ is indicated for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin. It is not intended for non-squamous NSCLC.
vectibix
(panitumumab)
Amgen Inc
Usage: Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as first-line therapy with FOLFOX or as monotherapy after prior chemotherapy. It is also approved for KRAS G12C-mutated mCRC in combination with sotorasib in previously treated patients.

Epidermal Growth Factor Receptor Antagonist class drugs

erbitux